Showing results (291-300 of 344) with videos related to
Sort By:
Pageof 35
International Journal of Hematology|June 14, 2022
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myelomaSatsuki Murakami, Masaki Ri, Masato Ito, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 8, 2017
[Lenalidomide and low-dose dexamethasone therapy for Japanese patients with newly diagnosed multiple myeloma: updated results of the MM-025 study]Kiyoshi Ando, Takaaki Chou, Kenshi Suzuki, et al.Cancer Medicine|April 27, 2023
Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasiaTomotaka Suzuki, Shigeru Kusumoto, Yoshiko Kamezaki, et al.Journal of Cancer Research and Clinical Oncology|August 28, 2020
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial resultsSaad Z Usmani, Maria-Victoria Mateos, Vania Hungria, et al.Haematologica|April 14, 2022
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphomaNorio Tanaka, Seiichi Mori, Kazuma Kiyotani, et al.Journal of Cancer|May 7, 2014
Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patientsYumiko Sato, Masahiro Kondo, Atsushi Inagaki, et al.British Journal of Haematology|November 20, 2020
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II studyAjai Chari, Paula Rodriguez-Otero, Helen McCarthy, et al.Clinical Lymphoma, Myeloma & Leukemia|May 31, 2022
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup AnalysisKazutaka Sunami, Takashi Ikeda, Shang-Yi Huang, et al.British Journal of Haematology|July 28, 2021
A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survivalTakeshi Yamashita, Hiroyuki Takamatsu, Koji Kawamura, et al.International Journal of Hematology|March 6, 2009
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemiaHisashi Sakamaki, Ken-Ichi Ishizawa, Masafumi Taniwaki, et al.Pageof 35